(Total Views: 539)
Posted On: 06/08/2018 11:13:36 AM
Post# of 47159

$AMBS Amarantus recently received an independent third-party valuation report which valued the Parkinson's disease levodopa-induced dyskinesia (PD-LID) indication for Eltoprazine in the US and Europe at $316 million.
https://finance.yahoo.com/news/amarantus-prov...46167.html
$AMBS
https://finance.yahoo.com/news/amarantus-prov...46167.html
$AMBS


Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!